Hyodeoxycholic acid inhibits colorectal cancer proliferation through the FXR/EREG/EGFR axis

BackgroundThe high morbidity and mortality rates of colorectal cancer (CRC) have been a public health concern globally, and the search for additional therapeutic options is imminent. Hyodeoxycholic acid (HDCA) has been receiving attention in recent years and has demonstrated potent efficacy in sever...

Full description

Saved in:
Bibliographic Details
Main Authors: Qiang Pang, Shansong Huang, Xiaodong Li, Jiaqing Cao
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-01-01
Series:Frontiers in Cell and Developmental Biology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fcell.2024.1480998/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1841558700909658112
author Qiang Pang
Shansong Huang
Xiaodong Li
Jiaqing Cao
author_facet Qiang Pang
Shansong Huang
Xiaodong Li
Jiaqing Cao
author_sort Qiang Pang
collection DOAJ
description BackgroundThe high morbidity and mortality rates of colorectal cancer (CRC) have been a public health concern globally, and the search for additional therapeutic options is imminent. Hyodeoxycholic acid (HDCA) has been receiving attention in recent years and has demonstrated potent efficacy in several diseases. Nonetheless, the antitumor effects and molecular pathways of HDCA in CRC remain largely unexplored.MethodsIn this study, we investigated how HDCA influences the growth potential of CRC cells using techniques such as flow cytometry, Edu assay, CCK-8, colony formation assay, Western blot analysis, and animal experiments.ResultsIt was found that HDCA treatment of CRC cells was able to significantly inhibit the proliferative capacity of the cells. Furthermore, it was discovered that HDCA primarily stimulated Farnesoid X Receptor (FXR) rather than Takeda G protein coupled receptor 5 (TGR5) to suppress CRC growth. It was also confirmed that HDCA inhibited the Epiregulin (EREG)/Epidermal Growth Factor Receptor (EGFR) pathway by activating FXR, and a negative correlation between FXR and EREG was analyzed in CRC tissue samples. Finally, in vivo animal studies confirmed that HDCA inhibited CRC proliferation without hepatotoxicity.ConclusionOur findings indicate that HDCA suppresses the EREG/EGFR signaling route by activating FXR, thereby hindering the growth of CRC cells and demonstrating a tumor-inhibiting effect in CRC. This study may provide a new therapeutic strategy to improve the prognosis of CRC.
format Article
id doaj-art-74e7203adc9e4c1fad012a338ec0b57a
institution Kabale University
issn 2296-634X
language English
publishDate 2025-01-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Cell and Developmental Biology
spelling doaj-art-74e7203adc9e4c1fad012a338ec0b57a2025-01-06T06:59:30ZengFrontiers Media S.A.Frontiers in Cell and Developmental Biology2296-634X2025-01-011210.3389/fcell.2024.14809981480998Hyodeoxycholic acid inhibits colorectal cancer proliferation through the FXR/EREG/EGFR axisQiang PangShansong HuangXiaodong LiJiaqing CaoBackgroundThe high morbidity and mortality rates of colorectal cancer (CRC) have been a public health concern globally, and the search for additional therapeutic options is imminent. Hyodeoxycholic acid (HDCA) has been receiving attention in recent years and has demonstrated potent efficacy in several diseases. Nonetheless, the antitumor effects and molecular pathways of HDCA in CRC remain largely unexplored.MethodsIn this study, we investigated how HDCA influences the growth potential of CRC cells using techniques such as flow cytometry, Edu assay, CCK-8, colony formation assay, Western blot analysis, and animal experiments.ResultsIt was found that HDCA treatment of CRC cells was able to significantly inhibit the proliferative capacity of the cells. Furthermore, it was discovered that HDCA primarily stimulated Farnesoid X Receptor (FXR) rather than Takeda G protein coupled receptor 5 (TGR5) to suppress CRC growth. It was also confirmed that HDCA inhibited the Epiregulin (EREG)/Epidermal Growth Factor Receptor (EGFR) pathway by activating FXR, and a negative correlation between FXR and EREG was analyzed in CRC tissue samples. Finally, in vivo animal studies confirmed that HDCA inhibited CRC proliferation without hepatotoxicity.ConclusionOur findings indicate that HDCA suppresses the EREG/EGFR signaling route by activating FXR, thereby hindering the growth of CRC cells and demonstrating a tumor-inhibiting effect in CRC. This study may provide a new therapeutic strategy to improve the prognosis of CRC.https://www.frontiersin.org/articles/10.3389/fcell.2024.1480998/fullcolorectal cancerHyodeoxycholic acidFXREREGEGFR
spellingShingle Qiang Pang
Shansong Huang
Xiaodong Li
Jiaqing Cao
Hyodeoxycholic acid inhibits colorectal cancer proliferation through the FXR/EREG/EGFR axis
Frontiers in Cell and Developmental Biology
colorectal cancer
Hyodeoxycholic acid
FXR
EREG
EGFR
title Hyodeoxycholic acid inhibits colorectal cancer proliferation through the FXR/EREG/EGFR axis
title_full Hyodeoxycholic acid inhibits colorectal cancer proliferation through the FXR/EREG/EGFR axis
title_fullStr Hyodeoxycholic acid inhibits colorectal cancer proliferation through the FXR/EREG/EGFR axis
title_full_unstemmed Hyodeoxycholic acid inhibits colorectal cancer proliferation through the FXR/EREG/EGFR axis
title_short Hyodeoxycholic acid inhibits colorectal cancer proliferation through the FXR/EREG/EGFR axis
title_sort hyodeoxycholic acid inhibits colorectal cancer proliferation through the fxr ereg egfr axis
topic colorectal cancer
Hyodeoxycholic acid
FXR
EREG
EGFR
url https://www.frontiersin.org/articles/10.3389/fcell.2024.1480998/full
work_keys_str_mv AT qiangpang hyodeoxycholicacidinhibitscolorectalcancerproliferationthroughthefxreregegfraxis
AT shansonghuang hyodeoxycholicacidinhibitscolorectalcancerproliferationthroughthefxreregegfraxis
AT xiaodongli hyodeoxycholicacidinhibitscolorectalcancerproliferationthroughthefxreregegfraxis
AT jiaqingcao hyodeoxycholicacidinhibitscolorectalcancerproliferationthroughthefxreregegfraxis